论文部分内容阅读
目的探讨阿托伐他汀不同剂量对急性脑梗死患者高敏C反应蛋白水平的影响。方法 80例急性脑梗死患者随机分为观察组和对照组,各40例。对照组采用常规的急性脑梗死治疗,同时给予小剂量阿托伐他汀治疗(服用10 mg/d)、观察组同时给予大剂量阿托伐他汀治疗(服用40 mg/d)。观察两组患者治疗前和治疗后不同时间的高敏C反应蛋白水平改变情况。结果观察组患者治疗后的第1天、第2天和第7天的高敏C反应蛋白水平分别低于本组治疗前,差异有统计学意义(P<0.05);对照组治疗后的第1天、第2天和第7天的高敏C反应蛋白水平分别低于本组治疗前,差异有统计学意义(P<0.05);观察组治疗后的第1天、第2天和第7天高敏C反应蛋白水平分别低于对照组同期的高敏C反应蛋白水平,差异有统计学意义(P<0.05)。结论大剂量阿托伐他汀能够显著降低急性脑梗死患者高敏C反应蛋白水平,抑制急性脑梗死炎症反应效果更显著,值得借鉴。
Objective To investigate the effect of different dosages of atorvastatin on high-sensitivity C-reactive protein in patients with acute cerebral infarction. Methods Eighty patients with acute cerebral infarction were randomly divided into observation group and control group, 40 cases in each. The control group using conventional treatment of acute cerebral infarction, while the low dose treatment with atorvastatin (administered 10 mg / d), while the high dose group was observed atorvastatin therapy (administered 40 mg / d). The changes of hypersensitivity C-reactive protein level before and after treatment in both groups were observed. Results after 1 day of observation group patients, 2 and 7 days of high-sensitivity C-reactive protein levels were lower than the group before treatment, there is statistically significant (P <0.05); the control group after first treatment Day, day 2 and day 7 were significantly lower than those before treatment in this group (P <0.05). On the 1st day, the 2nd day and the 7th day after the treatment, the high-sensitivity C-reactive protein High-sensitivity C-reactive protein levels were lower than the control group of high-sensitive C-reactive protein levels, the difference was statistically significant (P <0.05). Conclusion High-dose atorvastatin can significantly reduce the level of high-sensitivity C-reactive protein in patients with acute cerebral infarction, inhibit the inflammatory response of acute cerebral infarction more significantly and is worth learning from.